Today, Organon announces the launch of AnesthesiaNow, a new and free online professional information service for anesthesiologists around the world. AnesthesiaNow offers a comprehensive, high-quality and unbiased information resource to help healthcare professionals stay up-to-date with the latest developments.
anesthesianow
The content of AnesthesiaNow is guided by an independent advisory board consisting of Professor Paul G. Barash (USA), Professor Jerrold H. Levy (USA) and Professor Rajinder K. Mirakhur (UK). The site is managed by the Current Medicine Group and is supported by an educational grant from Organon.
AnesthesiaNow offers subscribers a wealth of specialist information at no cost including:
_-- An online literature service with links to full text articles from leading medical journals
_-- Featured articles providing a concise review of the latest research and clinical trial findings
_-- Monthly e-mail alerts to ensure that subscribers have instant access to the latest developments in anesthesia
Future content of the site will be determined through continued close collaboration with leading anesthesiologists and feedback from its users and may include topics such as:
_-- Case studies
_-- Conference reports
_-- Links to key journal sites, congresses and other useful online information.
"AnesthesiaNow is a new educational site that has been developed to help clinicians in anesthesiology keep up-to-date with a minimum of effort as well as supporting their attempts to track down information they need," says Professor Paul Barash, Advisory Board Member and Professor of Anesthesiology at Yale Medical School in New Haven, Connecticut, USA. "It provides a great deal of information tailored to the interests and needs of healthcare professionals and researchers in the Anesthesia community"
Healthcare professionals can subscribe to the site by visiting anesthesianow.
Organon has long been a pioneer within the field of anesthesia providing innovative products over the past 35 years. It is best known in the field for its portfolio of muscle relaxants of which EsmeronŽ (rocuronium bromide) is the most well known and commonly prescribed. As a leader in muscle relaxants and objective neuromuscular monitoring, the company remains fully committed to the research and development of products that optimize patient safety, improve patient care and therapeutic cost-effectiveness.
Organon - with shared head offices in Roseland, New Jersey, U.S.A. and Oss, The Netherlands - creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. Additional information about Organon is available through its corporate website, wwwanon.
For more information, please contact:
Monique Mols, Associate Director, Media Relations
Tel: +31-(0)412-665440, e-mail: monique.molsorganon
Safe Harbor Statement*
This report contains statements which address such key issues as Organon's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook," should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website akzonobel.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.